Tomorrow's targeted therapies in breast cancer patients: What is the risk for increased radiation-induced cardiac toxicity?
Nicolas Magné, Cyrus Chargari, Dhara MacDermed, Rosa Conforti, Lionel Védrine, Jean-Philippe Spano, David Khayat
20101101
2010 Dec 1
Crit Rev Oncol Hematol
Tomorrow's targeted therapies in breast cancer patients: What is the risk for increased radiation-induced cardiac toxicity?
Crit Rev Oncol Hematol. 2010 Dec;76(3):186-195, Nicolas Magné, Cyrus Chargari, Dhara MacDermed, Rosa Conforti, Lionel Védrine, Jean-Philippe Spano, David Khayat
Abstract
Abstract
Ongoing clinical trials are now investigating the benefits of new targeted therapies, including ErbB and tyrosine kinase inhibitors (TKI) and antiangiogenics. Those may carry a potential risk for additional cardiac toxicity, particularly in association with radiotherapy. Although the risk of symptomatic cardiotoxicity is low, more subtle functional declines may increase mortality with longer follow-up and necessitate caution when assessing concurrent or sequential trastuzumab or lapatinib with radiotherapy....
